Population Pharmacokinetics of BMN 673, a Novel PARP Inhibitor, in Beagle Dogs

被引：0
|
作者：
Qi, Yulan [1 ]
Musson, Don [1 ]
Tsuruda, Laurie [1 ]
Zhou, Huiyu [1 ]
Cheng, Alphonsus [1 ]
O'Neill, Charles [1 ]
机构：
[1] BioMarin Pharmaceut Inc, Novato, CA 94949 USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2013年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
下载
收藏
页码：S30 / S30
页数：1
相关论文
共 50 条
  • [21] Pilot trial of talazoparib (BMN 673), an oral PARP inhibitor, in patients with advanced solid tumors carrying deleterious BRCA mutations
    Meehan, Robert S.
    Chen, Alice P.
    Coyne, Geraldine O'Sullivan
    Kummar, Shivaani
    Ji, Jiuping
    Vilimas, Rasa
    Juwara, Lamin
    Kinders, Robert J.
    Ferry-Galow, Katherine
    Wilsker, Deborah
    Zhang, Yiping
    Dull, Angie B.
    Navas, Tony
    Wang, Lihua
    Parchment, Ralph E.
    Doroshow, James H.
    CANCER RESEARCH, 2017, 77
  • [22] Stereospecific trapping of PARP-DNA complexes by BMN 673 and comparison with olaparib and rucaparib
    Murai, Junko
    Huang, Shar-yin N.
    Renaud, Amelie
    Zhang, Yiping
    Ji, Jiuping
    Takeda, Shunichi
    Morris, Joel
    Teicher, Beverly
    Doroshow, James H.
    Pommier, Yves
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [23] BMN 673 is a PARP inhibitor in clinical development for the treatment of breast cancer patients with deleterious germline BRCA 1 and 2 mutations
    Mina, L. A.
    Ramanathan, R. K.
    Wainberg, Z. A.
    Byers, L. A.
    Chugh, R.
    Sachdev, J. C.
    Matei, D.
    Zhang, C.
    Henshaw, J. W.
    Dorr, A.
    Kaye, S. B.
    de Bono, J. S.
    CANCER RESEARCH, 2013, 73
  • [24] Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer
    Eskiler, G. Guney
    Cecener, G.
    Egeli, U.
    Tunca, B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [25] The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1-/- murine model of ovarian cancer
    Huang, Jing
    Wang, Lei
    Cong, Zhongyi
    Amoozgar, Zohreh
    Kiner, Evgeny
    Xing, Deyin
    Orsulic, Sandra
    Matulonis, Ursula
    Goldberg, Michael S.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2015, 463 (04) : 551 - 556
  • [26] Impact of Interindividual Differences in Plasma Fraction Unbound on the Pharmacokinetics of a Novel Syk Kinase Inhibitor in Beagle Dogs
    Pike, Andy
    Jones, Barry
    Markandu, Roshini
    O'Neill, Daniel
    DRUG METABOLISM AND DISPOSITION, 2021, 49 (09) : 736 - 742
  • [27] Pharmacokinetics of astragalosideiv in beagle dogs
    Qi Zhang
    Ling-Ling Zhu
    Guo-Guang Chen
    Yu Du
    European Journal of Drug Metabolism and Pharmacokinetics, 2007, 32 : 75 - 79
  • [28] The combination of the PARP inhibitor talazoparib (BMN 673) with the ATR inhibitor VE-821 overcomes the drug resistance of Schlafen 11-deficient cells
    Murai, Junko
    Pommier, Yves
    CANCER RESEARCH, 2015, 75
  • [29] Pharmacokinetics of Riluzole in Beagle Dogs
    Perdigao, Ana P. L.
    Antunes, Natalicia de Jesus
    Juni, Lucas T.
    de Freitas, Noedi L.
    Rojas-Moscoso, Julio
    Correa, Silvia V. M.
    da Costa, Ronaldo C.
    Moreno, Ronilson A.
    Mendes, Gustavo D.
    de Nucci, Gilberto
    DRUG RESEARCH, 2019, 69 (01) : 40 - 45
  • [30] Pharmacokinetics of tildipirosin in beagle dogs
    Wang, J.
    Zhao, T.
    Sun, X.
    Liu, Y.
    Zhu, J.
    Zhang, S.
    Cao, X.
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2018, 41 (01) : E49 - E52
12345